Low levels of insulin-like growth factor-1 contribute to alveolar macrophage dysfunction in cystic fibrosis

Journal of Immunology

Volumn 191, Issue 1, 2013, Pages 378-385

  Bessich, Jamie L ^a   Nymon, Amanda B ^b   Moulton, Lisa A ^a,b   Dorman, Dana ^a,b   Ashare, Alix ^a,b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C;

ADULT; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; INFECTION; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MACROPHAGE FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA;

ADULT; BLOOD CIRCULATION; BRONCHOALVEOLAR LAVAGE; CHRONIC DISEASE; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MACROPHAGES, ALVEOLAR; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; YOUNG ADULT;

EID: 84879639251     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300221     Document Type: Article

References (39)

1. Rowe, S. M., S. Miller, and E. J. Sorscher. 2005. Cystic fibrosis. N. Engl. J. Med. 352: 1992-2001. (Pubitemid 40638370)
2. Deriy, L. V., E. A. Gomez, G. Zhang, D. W. Beacham, J. A. Hopson, A. J. Gallan, P. D. Shevchenko, V. P. Bindokas, and D. J. Nelson. 2009. Disease-causing mutations in the cystic fibrosis transmembrane conductance regulator determine the functional responses of alveolar macrophages. J. Biol. Chem. 284: 35926-35938.
3. Di, A., M. E. Brown, L. V. Deriy, C. Li, F. L. Szeto, Y. Chen, P. Huang, J. Tong, A. P. Naren, V. Bindokas, et al. 2006. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat. Cell Biol. 8: 933-944. (Pubitemid 44314724)
4. Stoltz, D. A., D. K. Meyerholz, A. A. Pezzulo, S. Ramachandran, M. P. Rogan, G. J. Davis, R. A. Hanfland, C. Wohlford-Lenane, C. L. Dohrn, J. A. Bartlett, et al. 2010. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci. Transl. Med. 2: 29ra31.
5. Del Porto, P., N. Cifani, S. Guarnieri, E. G. Di Domenico, M. A. Mariggiò, F. Spadaro, S. Guglietta, M. Anile, F. Venuta, S. Quattrucci, and F. Ascenzioni. 2011. Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa. PLoS ONE 6: e19970.
6. Street, M. E., C. Spaggiari, M. A. Ziveri, C. Volta, G. Federico, G. I. Baroncelli, S. Bernasconi, and G. Saggese. 2006. Analysis of bone mineral density and turnover in patients with cystic fibrosis: associations between the IGF system and inflammatory cytokines. Horm. Res. 66: 162-168. (Pubitemid 44413276)
7. Street, M. E., M. A. Ziveri, C. Spaggiari, I. Viani, C. Volta, G. L. Grzincich, R. Virdis, and S. Bernasconi. 2006. Inflammation is a modulator of the insulinlike growth factor (IGF)/IGF-binding protein system inducing reduced bioactivity of IGFs in cystic fibrosis. Eur. J. Endocrinol. 154: 47-52. (Pubitemid 43250735)
8. Switzer, M., J. Rice, M. Rice, and D. S. Hardin. 2009. Insulin-like growth factor-I levels predict weight, height and protein catabolism in children and adolescents with cystic fibrosis. J. Pediatr. Endocrinol. Metab. 22: 417-424.
9. Teng Chung, T., and C. J. Hinds. 2006. Treatment with GH and IGF-1 in critical illness. Crit. Care Clin. 22: 29-40, vi. (Pubitemid 43037108)
10. Karey, K. P., and D. A. Sirbasku. 1988. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res. 48: 4083-4092.
11. Kibbey, M. M., M. J. Jameson, E. M. Eaton, and S. A. Rosenzweig. 2006. Insulin-like growth factor binding protein-2: contributions of the C-terminal domain to insulin-like growth factor-1 binding. Mol. Pharmacol. 69: 833-845. (Pubitemid 43363858)
12. Ashare, A., A. B. Nymon, K. C. Doerschug, J. M. Morrison, M. M. Monick, and G. W. Hunninghake. 2008. Insulin-like growth factor-1 improves survival in sepsis via enhanced hepatic bacterial clearance. Am. J. Respir. Crit. Care Med. 178: 149-157. (Pubitemid 351957773)
13. Hunninghake, G. W., K. C. Doerschug, A. B. Nymon, G. A. Schmidt, D. K. Meyerholz, and A. Ashare. 2010. Insulin-like growth factor-1 levels contribute to the development of bacterial translocation in sepsis. Am. J. Respir. Crit. Care Med. 182: 517-525.
14. Ahmed, T. A., M. D. Buzzelli, C. H. Lang, J. B. Capen, M. L. Shumate, M. Navaratnarajah, M. Nagarajan, and R. N. Cooney. 2007. Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G1793-G1803. (Pubitemid 47080598)
15. Cooney, R. N., and M. Shumate. 2006. The inhibitory effects of interleukin-1 on growth hormone action during catabolic illness. Vitam. Horm. 74: 317-340.
16. Ahmed, T., G. Yumet, M. Shumate, C. H. Lang, P. Rotwein, and R. N. Cooney. 2006. Tumor necrosis factor inhibits growth hormone-mediated gene expression in hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 291: G35-G44. (Pubitemid 44024660)
17. Shumate, M. L., G. Yumet, T. A. Ahmed, and R. N. Cooney. 2005. Interleukin-1 inhibits the induction of insulin-like growth factor-I by growth hormone in CWSV-1 hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G227-G239. (Pubitemid 41022748)
18. Yumet, G., M. L. Shumate, P. Bryant, C. M. Lin, C. H. Lang, and R. N. Cooney. 2002. Tumor necrosis factor mediates hepatic growth hormone resistance during sepsis. Am. J. Physiol. Endocrinol. Metab. 283: E472-E481. (Pubitemid 35230484)
19. Rogan, M. P., L. R. Reznikov, A. A. Pezzulo, N. D. Gansemer, M. Samuel, R. S. Prather, J. Zabner, D. C. Fredericks, P. B. McCray, Jr., M. J. Welsh, and D. A. Stoltz. 2010. Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth. Proc. Natl. Acad. Sci. USA 107: 20571-20575.
20. Geertz, R., W. Kiess, U. Kessler, A. Hoeflich, A. Tarnok, and G. Gercken. 1997. Expression of IGF receptors on alveolar macrophages: IGF-induced changes in InsPi formation, [Ca2+]i, and pHi. Mol. Cell. Biochem. 177: 33-45.
21. Balteskard, L., K. Unneberg, D. Halvorsen, J. B. Hansen, and A. Revhaug. 1998. Effects of insulin-like growth factor 1 on neutrophil and monocyte functions in normal and septic states. JPEN J. Parenter. Enteral Nutr. 22: 127-135. (Pubitemid 28194468)
22. Flaherty, D. M., M. M. Monick, and S. L. Hinde. 2006. Human alveolar macrophages are deficient in PTEN. The role of endogenous oxidants. J. Biol. Chem. 281: 5058-5064. (Pubitemid 43847771)
23. Monick, M. M., L. S. Powers, C. W. Barrett, S. Hinde, A. Ashare, D. J. Groskreutz, T. Nyunoya, M. Coleman, D. R. Spitz, and G.W. Hunninghake. 2008. Constitutive ERK MAPK activity regulates macrophage ATP production and mitochondrial integrity. J. Immunol. 180: 7485-7496.
24. Smith, E. E., D. G. Buckley, Z. Wu, C. Saenphimmachak, L. R. Hoffman, D. A. D'Argenio, S. I. Miller, B. W. Ramsey, D. P. Speert, S. M. Moskowitz, et al. 2006. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl. Acad. Sci. USA 103: 8487-8492. (Pubitemid 43838482)
25. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3: 23-35. (Pubitemid 37328697)
26. Gordon, S., and F. O. Martinez. 2010. Alternative activation of macrophages: mechanism and functions. Immunity 32: 593-604.
27. Ma, J., T. Chen, J. Mandelin, A. Ceponis, N. E. Miller, M. Hukkanen, G. F. Ma, and Y. T. Konttinen. 2003. Regulation of macrophage activation. Cell. Mol. Life Sci. 60: 2334-2346. (Pubitemid 37487255)
28. Martinez, F. O., L. Helming, and S. Gordon. 2009. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27: 451-483.
29. Murphy, B. S., H. M. Bush, V. Sundareshan, C. Davis, J. Hagadone, T. J. Cory, H. Hoy, D. Hayes, Jr., M. I. Anstead, and D. J. Feola. 2010. Characterization of macrophage activation states in patients with cystic fibrosis. J. Cyst. Fibros. 9: 314-322.
30. Rubins, J. B. 2003. Alveolar macrophages: wielding the double-edged sword of inflammation. Am. J. Respir. Crit. Care Med. 167: 103-104. (Pubitemid 36076064)
31. Mosser, D. M., and J. P. Edwards. 2008. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8: 958-969.
32. Chen, W. H., F. R. Toapanta, K. A. Shirey, L. Zhang, A. Giannelou, C. Page, M. B. Frieman, S. N. Vogel, and A. S. Cross. 2012. Potential role for alternatively activated macrophages in the secondary bacterial infection during recovery from influenza. Immunol. Lett. 141: 227-234.
33. Varin, A., S. Mukhopadhyay, G. Herbein, and S. Gordon. 2010. Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial-induced signalling and cytokine secretion. Blood 115: 353-362.
34. Page, C., L. Goicochea, K. Matthews, Y. Zhang, P. Klover, M. J. Holtzman, L. Hennighausen, and M. Frieman. 2012. Induction of alternatively activated macrophages enhances pathogenesis during severe acute respiratory syndrome coronavirus infection. J. Virol. 86: 13334-13349.
35. Barriere, H., M. Bagdany, F. Bossard, T. Okiyoneda, G. Wojewodka, D. Gruenert, D. Radzioch, and G. L. Lukacs. 2009. Revisiting the role of cystic fibrosis transmembrane conductance regulator and counterion permeability in the pH regulation of endocytic organelles. Mol. Biol. Cell 20: 3125-3141.
36. Haggie, P. M., and A. S. Verkman. 2009. Defective organellar acidification as a cause of cystic fibrosis lung disease: reexamination of a recurring hypothesis. Am. J. Physiol. Lung Cell. Mol. Physiol. 296: L859-L867.
37. Li, L., D. He, T. W. Wilborn, J. L. Falany, and C. N. Falany. 2009. Increased SULT1E1 activity in HepG2 hepatocytes decreases growth hormone stimulation of STAT5b phosphorylation. Steroids 74: 20-29.
38. Furundzija, V., J. Fritzsche, J. Kaufmann, H. Meyborg, E. Fleck, K. Kappert, and P. Stawowy. 2010. IGF-1 increases macrophage motility via PKC/p38-dependent alphavbeta3-integrin inside-out signaling. Biochem. Biophys. Res. Commun. 394: 786-791.
39. Ozen, M., H. Cokugras, N. Ozen, Y. Camcioglu, and N. Akcakaya. 2004. Relation between serum Insulin-like growth factor-I and insulin-like growth factor-binding protein-3 levels, clinical status and growth parameters in prepubertal cystic fibrosis patients. Pediatr. Int. 46: 429-435. (Pubitemid 39119156)